Nanotechnology Now - Press Release: "Recent News Stories Highlight Stellar Biotechnologies: Stellar Biotechnologies Featured in National Cancer Institute (NCI) Success Story and Popular Science Magazine Article"

Home > Press > Recent News Stories Highlight Stellar Biotechnologies: Stellar Biotechnologies Featured in National Cancer Institute (NCI) Success Story and Popular Science Magazine Article

Abstract:
Stellar Biotechnologies, Inc. "Stellar" (TSX-V: KLH) (PINKSHEETS: SBOTF) is pleased to report two recent news stories on the company, by the National Cancer Institute (NCI) and in Popular Science magazine.

Recent News Stories Highlight Stellar Biotechnologies: Stellar Biotechnologies Featured in National Cancer Institute (NCI) Success Story and Popular Science Magazine Article

Port Hueneme, CA | Posted on November 23rd, 2011

The NCI story is a Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) "Success Story" featuring Stellar's technology platform, NCI SBIR awards and recent corporate partnerships.

The NCI's prestigious SBIR and STTR programs "foster research and development for anticancer agents, biomarkers, informatics, medical devices, nanotechnology, proteomics, pharmacodynamics, and many other biotechnologies and programs designed to prevent, diagnose, and treat cancer." The NCI Success Story on Stellar can be found here: sbir.cancer.gov/success/stories/stellar/stellar.asp or through sbir.cancer.gov/success/

Popular Science magazine's article "How Mollusk Blood Could Cure Cancer" covered the role of keyhole limpet hemocyanin (KLH) as an essential component in cancer vaccine research and Stellar's sustainable aquaculture practices.

Stellar notes that the Popular Science story included one error. Contrary to the article's report, Stellar's current manufacturing capacity (not output) is between one and two kilograms of KLH per year. The Popular Science story appears in both the December 2011 print edition (page 17) and in the magazine's POPSCI website.

Stellar Executive VP, Corporate Development & Finance, Darrell Brookstein, said, "KLH's long-standing importance in vaccine development and immunology is gaining popular attention of late. Stellar appreciates the recent recognition for our industry-leading best practices and our dedication to ensure supply of KLH, a critical natural resource."

Parties interested in regular updates and news of interest in related topics, please visit www.stellarbiotechnologies.com/investors/news_releases/ and enter email address at bottom of page.

####

About Stellar Biotechnologies, Inc.
Stellar Biotechnologies, Inc. (TSX-V: KLH) (PINKSHEETS: SBOTF) (www.StellarBiotechnologies.com) is the world leader in sustainable manufacturing of pharmaceutical grade KLH (Keyhole Limpet Hemocyanin). This evolutionary protein has a highly complex structure that makes it ideal for use in human and animal vaccines and diagnostic products. With partners and customers, its flagship Stellar KLH products are in the clinic, and on the way to being established as the only sustainable, long-term pharmaceutical source. Stellar Biotechnologies was founded to address the growing demand for renewable, commercial-scale supplies of high-quality, GMP-grade KLH. Stellar has developed leading practices, facilities and proprietary capabilities to address this need.

There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Readers should not place undue reliance on such statements. Except in accordance with applicable securities laws, the Company expressly disclaims any obligation to update any forward-looking statements or forward-looking statements that are incorporated by reference herein. This news release does not constitute an offer to sell, or a solicitation of an offer to buy any of the Company's securities set out herein in the United States, or to, or for the benefit or account of, a U.S. Person or person in the United States. Neither TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of these releases.

For more information, please click here

Contacts:
Darrell Brookstein
Executive VP
Stellar Biotechnologies, Inc.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark: